Skip to content

BetaGlue Appoints Salvatore Calabrese as Chief Financial Officer

Salvatore Calabrese CFO, BetaGlue

Milan, January 15, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products with a primary focus in the field of loco- regional radiotherapy to treat solid tumour cancers, today announced the appointment of Salvatore Calabrese as the Company’s Chief Financial Officer. Salvatore brings a wealth of leadership experience in corporate strategies, management, finance and governance matured over 20 years of experience as CFO for publicly traded and private companies in the life sciences sector.

“We are delighted to welcome Salvatore to our team. He brings an enviable track record in developing and executing on financial, strategic planning and operations, capital market strategies as well as investor relations” said Dr Colin Story, Chief Executive Officer. “Salvatore is well placed to support BetaGlue into its next phase of growth. His international experience and financial expertise make him the ideal candidate to support BetaGlue in achieving its strategic objectives and drive the mission to address major unmet clinical need in a range of solid tumour cancer patient groups. I would also like to take this opportunity to thank Giovanni Parisio for his many years of contribution and dedicated support to BetaGlue”.

Before joining BetaGlue, Salvatore has worked across large global business and small growing companies and held executive positions at Gentium S.p.A. (Nasdaq: GENT), Jazz Pharmaceuticals (Nasdaq: JAZZ), MolMed S.p.A. (MI.MLMD) and Gain Therapeutics Inc. (Nasdaq: GANX).

“I am extremely honoured and excited to be joining BetaGlue as Chief Financial Officer and grateful for the trust and support from the management team and the Board,” said Salvatore. “I look forward to being part of a high-standing professional team and committed to BetaGlue’s goals to address important innovations in the field of loco-regional radiotherapy to treat solid tumour cancers and to offer potentially life-saving therapies to patients in dire need”.

About BetaGlue Technologies S.p.A.

BetaGlue Technologies S.p.A is a clinical-stage oncology company developing a novel radiotherapy platform technology for the localised and targeted treatment of unresectable solid tumours. BetaGlue enjoys the support of a global Scientific Advisory Board, as well as of leading national and international advisers, in the development of its products.

LinkedIn: Here